KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Retained Earnings (2018 - 2025)

Adaptive Biotechnologies' Retained Earnings history spans 8 years, with the latest figure at $253000.0 for Q4 2025.

  • For Q4 2025, Retained Earnings rose 52.41% year-over-year to $253000.0; the TTM value through Dec 2025 reached $253000.0, up 52.41%, while the annual FY2025 figure was $253000.0, 52.41% up from the prior year.
  • Retained Earnings for Q4 2025 was $253000.0 at Adaptive Biotechnologies, up from $211000.0 in the prior quarter.
  • Across five years, Retained Earnings topped out at $631000.0 in Q1 2021 and bottomed at -$1.1 billion in Q4 2023.
  • The 5-year median for Retained Earnings is -$144000.0 (2024), against an average of -$277.0 million.
  • The largest annual shift saw Retained Earnings tumbled 386059.72% in 2022 before it skyrocketed 226.42% in 2025.
  • A 5-year view of Retained Earnings shows it stood at -$718.9 million in 2021, then soared by 99.43% to -$4.1 million in 2022, then crashed by 27702.04% to -$1.1 billion in 2023, then skyrocketed by 100.01% to $166000.0 in 2024, then skyrocketed by 52.41% to $253000.0 in 2025.
  • Per Business Quant, the three most recent readings for ADPT's Retained Earnings are $253000.0 (Q4 2025), $211000.0 (Q3 2025), and $73000.0 (Q2 2025).